僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Bimekizumab （Anti-Human IL17A/IL-17F Recombinant Antibody） is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell （hPDC） differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation